[技术与生物制药方面。口服抗血小板药物] - Suppr

Suppr

超能文献

[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].

作者信息

Breitkreutz Jörg

机构信息

Institut für Pharmazeutische Technologie und Biopharmazie, Universitätsstrasse 1, 40225 Düsseldorf.

出版信息

Pharm Unserer Zeit. 2009;38(4):330-7. doi: 10.1002/pauz.200900322.

DOI:10.1002/pauz.200900322

PMID:19572353

Abstract

摘要

相似文献

[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].

Pharm Unserer Zeit. 2009;38(4):330-7. doi: 10.1002/pauz.200900322.

Bedside evaluation of thienopyridine antiplatelet therapy.

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732.

Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events.

BMJ. 2011 Jun 17;342:d3488. doi: 10.1136/bmj.d3488.

[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].

Pharm Unserer Zeit. 2009;38(4):320-8. doi: 10.1002/pauz.200900321.

[Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].

Pharm Unserer Zeit. 2009;38(4):342-50. doi: 10.1002/pauz.200900324.

Can we override clopidogrel resistance?

Circulation. 2009 Jun 2;119(21):2854-7. doi: 10.1161/CIRCULATIONAHA.108.857722.

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):593-618. doi: 10.1007/s10928-008-9103-7. Epub 2008 Nov 21.

[Pharmazie in unserer Zeit 4/2009].

Pharm Unserer Zeit. 2009;38(4):295. doi: 10.1002/pauz.200990042.

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.

Eur J Pharmacol. 2008 Jan 28;579(1-3):276-82. doi: 10.1016/j.ejphar.2007.10.005. Epub 2007 Oct 11.

Prasugrel (Effient) vs. clopidogrel (Plavix).

Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].

作者信息

Breitkreutz Jörg

机构信息

Institut für Pharmazeutische Technologie und Biopharmazie, Universitätsstrasse 1, 40225 Düsseldorf.

出版信息

Pharm Unserer Zeit. 2009;38(4):330-7. doi: 10.1002/pauz.200900322.

DOI:10.1002/pauz.200900322

PMID:19572353

Abstract

摘要

相似文献

[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].

Pharm Unserer Zeit. 2009;38(4):330-7. doi: 10.1002/pauz.200900322.

Bedside evaluation of thienopyridine antiplatelet therapy.

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732.

Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events.

BMJ. 2011 Jun 17;342:d3488. doi: 10.1136/bmj.d3488.

[Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].

Pharm Unserer Zeit. 2009;38(4):320-8. doi: 10.1002/pauz.200900321.

[Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].

Pharm Unserer Zeit. 2009;38(4):342-50. doi: 10.1002/pauz.200900324.

Can we override clopidogrel resistance?

Circulation. 2009 Jun 2;119(21):2854-7. doi: 10.1161/CIRCULATIONAHA.108.857722.

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):593-618. doi: 10.1007/s10928-008-9103-7. Epub 2008 Nov 21.

[Pharmazie in unserer Zeit 4/2009].

Pharm Unserer Zeit. 2009;38(4):295. doi: 10.1002/pauz.200990042.

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.

Eur J Pharmacol. 2008 Jan 28;579(1-3):276-82. doi: 10.1016/j.ejphar.2007.10.005. Epub 2007 Oct 11.

Prasugrel (Effient) vs. clopidogrel (Plavix).

Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70.